Trials / Recruiting
RecruitingNCT06610734
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 202 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined with Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Detailed description
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined with Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adebrelimab | Adebrelimab combined with chemotherapy synchronous LDRT |
| DRUG | Chemotherapy | Chemotherapy |
| RADIATION | low dose radiotherapy | low dose radiotherapy |
Timeline
- Start date
- 2024-12-23
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
- First posted
- 2024-09-24
- Last updated
- 2026-02-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06610734. Inclusion in this directory is not an endorsement.